|
проф. Н.И. Переводчикова Отделение химиотерапии РОНЦ им.Н.Н.Блохина РАМН, Москва
В начало
(Окончание)
Заключение
Современные возможности химиотерапии НМРЛ могут быть сформулированы следующим образом:
При диссеминированном НМРЛ комбинированная химиотерапия с использованием производных платины может контролировать заболевание и улучшает выживаемость больных по сравнению с использованием чисто симптоматической терапии.
Производные платины остаются основой современной комбинированной химиотерапии.
Использование новых противоопухолевых препаратов в сочетании с производными платины позволило достичь более высокого уровня выживаемости больных с распространенным НМРЛ.
До настоящего времени ни одна из эффективных современных комбинаций достоверно не может быть признана наилучшей.
Использование производных платины достоверно улучшает результаты лучевой терапии при местнораспространенном НМРЛ.
Предоперационная неоадъювантная химиотерапия и химиолучевая терапия с последующей операцией могут считаться апробированным методом и рассматриваться как один из вариантов лечения при III стадии НМРЛ.
Нет убедительных доказательств эффективности послеоперационной адъювантной химиотерапии при НМРЛ, хотя имеются основания для продолжения дальнейших клинических исследований в этом направлении.
Развитие трансляционных исследований по разработке новых терапевтических средств на основе данных о молекулярно-биологических особенностях НМРЛ позволяет надеяться на улучшение результатов лечения этой формы злокачественных новообразований.
Современная онкология, Том 1/N2/1999
Albain K.S., Crowley J.J., Le Blanc M. et al. Survival determinants in extensive stage non-small cell lung cancer. The Southwest Oncology Group experience. J. Clin. Oncol. 1991; 9: 1618-26.
Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in non small cell lung cancer. A metaanalysis using updated data on individual patients from 52 randomized clinical trials. British Medical J. 1995; 311(7010): 899-909.
Grilli R., Oxman A.D., Julian J.A. Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough. J. Clin. Oncol.1993; 11: 1866-72.
Smith I.E. Chemotherapy of advanced stage non SCLC. Impact on quality of life and symptom control. Lung Cancer, 1997; 18(suppl.2): 67.
Hopwood P. Evidence for the impact on quality of life. Lung Cancer, 1997; 18(suppl.2): 66.
Curan W.J. Issues in the nonoperative management of patients with locally advanced non-small cell lung cancer. Am. Soc. Clin. Oncol. Educational book, Ed. Perry M.C., ASCO, 1999; 370-3.
Dillman R.O., Herndon J., Seagren S.L. et al. Improved survival in stage III non-small cell lung cancer: Seven-year follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J. Nat. Cancer Inst. 1996; 88: 1210-5.
Le Chevalier T., Arriagada R., Quoix E. et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J. Nat. Cancer Inst. 1991; 83: 417-23.
Schaake-Koning, Van Den Bogert W., Dalesio O., et al. Effect of concomitant cisplatin and radiotherapy in inoperable non-small cell lung cancer. N. Engl. J. Med. 1992; 326: 524-30.
Sause W., Scott C., Taylor S. et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small cell lung cancer. J. Nat. Cancer. Inst. 1995; 87: 198-205.
Jeremic B., Shibamoto Y., Acimovie L. et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small cell lung cancer: A randomized study. J. Clin. Oncol. 1996; 14: 1065-70.
Rosell R., Gomez-Codina J., Camps C. et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. New Engl. J. of Med. 1994; 330(3): 153-8.
Roth J.A., Fossella F., Komaki R. et al. A randomized trial comparing perioperative chemotherapy and surgery alone in resectable stage IIIA non-small cell lung cancer. J. Natl. Cancer Inst. 1994; 86(9): 673-80.
Albain K.S., Rusch V.W., Crowley J.J. et al. Concurrent cispaltin/etoposide plus chest radiotherapy followed by surgery for stage IIIA (N2) and IIIB non-small cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J. of Clinical Oncology, 1995; 13(8): 1880-92.
Holmes A.C. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large cell undifferentiated carcinoma. Chest 1994; 106(6 suppl.): 293-6.
Lad T., Rubinstein L., Sadeghi A. The benefit of adjuvant treatment for resected locally advanced non-small cell lung cancer. J. Clin. Oncol. 1988; 6(1): 9-17.
Hansen H. Is there any impact of new drugs on the outcome of lung cancer. 23th ESMO Educational book, 1998; 27-31.
Johnson D.H. Paclitaxel-combination chemotherapy in non-small cell lung cancer. Lung Cancer, 1997; 18 (suppl. 2): 55-6.
Fossella F. Docetaxel (Doc) for non-small cell lung cancer. Lung Cancer, 1997; 18(suppl. 2): 62-3.
Hansen H. The effect of gemcitabine in NSCLC. Lung Cancer, 1997;18(suppl. 2): 60-1.
Le Chevalier T. Vinorelbine (Navelbine) in non-small cell carcinoma. Lung Cancer, 1997; 18(suppl 2): 58-9.
Fukuoka M. Camptothecines. Lung Cancer, 1997; 18(suppl 2): 57.
Le Chevalier T., Brisgand D., Doillard J.Y. et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small cell lung cancer: results of a European multicenter trial including 612 patients. J. Clin. Oncol. 1994; 12(2): 360-7.
Wоzniak A.J., Crawley J.J., Balcerzak S.P. et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbin in the treatment of advanced non-small cell lung cancer: A Southwest Oncology Group study. J. Clin. Oncol. 1998; 16(7): 2459-65.
Kelly K., Crowley J., Bunn R.B. et al. A randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cisplatin (VC) in untreated advanced non-small cell lung cancer (NSCLC). : A Southwest Oncology Group (SWOG) trial. Proceedings ASCO, 1999; 18: abstr. 1777.
Bonomi P., Kim K., Chang A. et al. Phase III trial comparing etoposide (E), cisplatin (C) versus Taxol (T) with cisplatin G-CSF (G) versus cisplatin in advanced non-small cell lung cancer (NSCLC): Esatern Cooperative Oncology Group (ECOG). Proc. Am. Soc. Clin. Oncol. 1996; 15: A1145.
Bonomi P., Kim K., Johnson D. Phase III experience with paclitaxel in non-small cell lung cancer. North American experience. In Taxanes in lung cancer therapy. ed. Johnson D. and Klastersky J., Marcel Dekker, NY, 1998; 81.
Giaccone G, Splinter T., Postmus P. et al. Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1996; 15: 373.
Gralla R.J. Docetaxel trials in non-small cell lung carcinoma. Taxanes in lung cancer ed. Johnson D., Klastersly J., Marcel Dekker, NY, 1998; 105-15.
Sandler A., Nemunaitis J., Dehnam C. et al. Phase III study of cisplatin (C) with or without gemcitabine (G) in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. 1998;17(abstr. 1747): 454a.
Crino L., Conte P., De Marinis F. et al. A randomized trial of gemcitabine cispaltin (CP) versus mitomycin, ifosfamide and cisplatin (MIC) in advanced non-small cell lung cancer. A multicenter phase III study. Proc. Am. Soc. Clin. Oncol. 1998; 17(abstr. 1750): 455a.
Gandara D.R., Edelman M.J., Lara P., Lan D. Current status and novel therapeutic approaches in advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol. Educational book ed. Perry M.C., ASCO, 1999.
Von Pawel J., Von Roemeling R. Survival benefit from Tirazone (tirapazamine) and cisplatin in advanced non-small cell lung cancer (NSCLC) patients. Final results from the phase III Catapult trial. Proc. Am. Soc. Clin. Oncol. 1749; 17, 454a, 1998, abstr.
Treat J., Haynes B., Johnson E. et al. Tirapazamine with cisplatin. A phase II trial in advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol. 1998; 16: 3524-7.
Kern J.A., Schwartz D.A., Nordberg J.E. et al. P185neu expression in human lung adenocarcinoma predicts shortened survival. Cancer Res. 1990; 50: 5184-91.
Jayson G.C., Crowther D., Prendiville J. et al. A phase I trial of bryostatin-1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br. J. Cancer, 1995; 72: 461-8.
Mack P.C., Edelman M.J., Gandara D.R. et al. Association of RB status with activity of combination 7 hydroxystaurosporine (UCN-01) plus cisplatin (CDDP) treatment in non-small cell carcinoma (NSCLC) cell lines. Proc. Am. Assoc. Cancer Res. 1998; 39: A1220.
Zujewski J., Horak I.D. Woestenborghs R. et al. Phase I trial of farnesyl-transferase inhibitor, R115777, in advanced cancer. Proc. Am. Assoc. Cancer Res. 1998; 39(abstr. 1848): 270.
Rasmussen H., Rugg T., Brown P. et al. A 371 patient metaanalysis of studies of marimostat in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol. 1997; 16(abstr.1538): 429.
Wojtowicz-Praga S., Torri J., Johnston M. et al. Phase I trial of marimostat a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. 1998; 16(6): 2150-5.
Rowinsky E., Hammond L., Aylesworth C. et al. Prolonged administration of BAY12-9566, an oral non-peptidic biphenyl matrix metalloproteinase (MMP) inhibitor: a phase I and pharmacokinetic study. Proc. Am. Soc. Clin. Oncol. 1998; 17(abstr. 836): 216a.
Gordon M.S., Talpaz M., Margolin E. et al. Phase I of recombinant humanized anti-vascular endothelial growth factor in patients with metastatic cancer. Proc. Am. Soc. Clin. Oncol. 1998; 17(abstr. 809): 210a.
Swisher S.G., Roth J.A., Lawrence D.D. et al. Adenoviralmediated p53 gene transfer in patients with advanced NSCLC. Proc. Am. Soc. Clin. Oncol. 1997; 16: 437a.
Gumerlock P.H. Molecular-clinical correlative studies in non-small cell lung carcinoma. In American Society of Clinical Oncology Educational book Ed.- Perry M.C., ASCO, 1999, 374-81.
Написать комментарий
|
